JTV-803 mesylate | CAS#247131-79-9 | 247131-06-2 | Xa inhibitor

MedKoo Cat#: 530413 | Name: JTV-803 mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JTV-803 is a factor Xa inhibitor potentially for the treatment of thrombosis. JTV-803 showed a competitive inhibitory effect on human factor Xa, with a K(i) value of 0.019 microM. JTV-803 was 100 times more selective in inhibiting human factor Xa as compared to its inhibitory activity against thrombin, plasmin, and trypsin. JTV-803 exerted a potent inhibitory effect on human factor Xa (IC(50): 0.081 microM). JTV-803 prolonged activated partial thromboplastin time and prothrombin time in a dose-dependent manner.

Chemical Structure

JTV-803 mesylate

CAS#247131-79-9 (mesylate)

Theoretical Analysis

MedKoo Cat#: 530413

Name: JTV-803 mesylate

CAS#: 247131-79-9 (mesylate)

Chemical Formula: C23H31N5O6S

Exact Mass:

Molecular Weight: 505.59

Elemental Analysis: C, 54.64; H, 6.18; N, 13.85; O, 18.99; S, 6.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

JTV-803; JTV 803; JTV803; JTV-803 mesylate.

IUPAC/Chemical Name

4-Piperidinecarboxylic acid, 4-(((2-(aminoiminomethyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)oxy)methyl)-1-(4-pyridinyl)-, methanesulfonate (1:1)

InChi Key

NOBZETMXGVAWIM-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H27N5O3.CH4O3S/c23-21(24)27-10-5-16-1-2-19(13-17(16)14-27)30-15-22(20(28)29)6-11-26(12-7-22)18-3-8-25-9-4-18;1-5(2,3)4/h1-4,8-9,13H,5-7,10-12,14-15H2,(H3,23,24)(H,28,29);1H3,(H,2,3,4)

SMILES Code

O=C(C1(COC2=CC3=C(C=C2)CCN(C(N)=N)C3)CCN(C4=CC=NC=C4)CC1)O.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 247131-06-2 (JTV-803 Free base) 247131-79-9 (JTV-803 mesylate)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 505.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gerotziafas GT, Samama MM. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des. 2005;11(30):3855-76. Review. PubMed PMID: 16305517. 2: Ueno H, Yokota K, Hoshi J, Yasue K, Hayashi M, Hase Y, Uchida I, Aisaka K, Katoh S, Cho H. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring. J Med Chem. 2005 May 19;48(10):3586-604. PubMed PMID: 15887966. 3: Ueno H, Yokota K, Hoshi J, Yasue K, Hayashi M, Uchida I, Aisaka K, Hase Y, Katoh S, Cho H. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors. Bioorg Med Chem Lett. 2005 Jan 3;15(1):185-9. PubMed PMID: 15582437. 4: Tobu M, Iqbal O, Hoppensteadt D, Neville B, Messmore HL, Fareed J. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost. 2004 Oct;10(4):301-9. PubMed PMID: 15497016. 5: Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost. 2004 Apr;2(4):612-8. PubMed PMID: 15102016. 6: Hayashi M, Uesato N, Aisaka K. Effects of activated factor X inhibitor, JTV-803, in a pig model of hemodialysis. Thromb Res. 2002 Sep 15;107(6):351-6. PubMed PMID: 12565723. 7: Tobu M, Iqbal O, Hoppensteadt DA, Shultz C, Jeske W, Fareed J. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests. Clin Appl Thromb Hemost. 2002 Oct;8(4):325-36. PubMed PMID: 12516682. 8: Asakura H, Ichino T, Yoshida T, Suga Y, Ontachi Y, Mizutani T, Kato M, Ito T, Yamazaki M, Aoshima K, Morishita E, Saito M, Miyamoto KI, Nakao S. Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models. Blood Coagul Fibrinolysis. 2002 Apr;13(3):233-9. PubMed PMID: 11943937. 9: Hayashi M, Hamada A, Okaya Y, Wakitani K, Aisaka K. Inhibitory effect of JTV-803, a new cyclic guanidine derivative, on factor Xa in vitro and in vivo. Eur J Pharmacol. 2001 Oct 5;428(2):163-8. PubMed PMID: 11675032. 10: Hayashi M, Matsuo A, Nakamoto H, Aisaka K. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals. Eur J Pharmacol. 2001 Jan 19;412(1):61-6. PubMed PMID: 11166737.